APERTO DCB a “very promising new technology” for central vein stenosis

NOTE: This video is ONLY available to watch in selected countries and geographies

“Patients who are on chronic dialysis really depend on arteriovenous (AV) access for their treatment,” Michael Lichtenberg (Arnsberg, Germany) tells Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain). “Unfortunately we know that AV access can have a lot of issues with stenosis or restenosis, which also counts for central veins. And if the central veins are blocked, it could mean that these patients lose their AV access for dialysis.”

“Unfortunately, standard balloon angioplasty is the most widely used therapy option at the moment” notes Lichtenberg, who adds however that “new technologies like drug-eluting balloon angioplasties are now coming into focus because we learnt that these new technologies have much better patency rates.”

Despite this, “you cannot use every drug-coated balloon (DCB) in this indication”, he says. For example, “for central vein stenosis you need large diameters, so therefore you need dedicated drug-coated balloons (DCBs) for these indications,” Lichtenberg explains.

The APERTO DCB technology (Cardionovum) is one of the very promising new technologies for this indication, believes Lichtenberg. He concludes by discussing an upcoming trial which will analyse the efficacy and safety of the device in this context. “We have already recruited a couple of patients and the interim data are very promising,” says Lichtenberg.

This video is sponsored by Cardionovum.

The post APERTO DCB a “very promising new technology” for central vein stenosis appeared first on Vascular News.